Seven biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
MEI Pharma, Inc. (MEIP) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. MEI Pharma is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. For more information, get Portfolio Grader’s complete analysis of MEIP stock.
PharmAthene, Inc. (PIP) shows solid improvement this week. The company’s rating rises from a C to a B. PharmAthene develops biological and chemical defense products. For more information, get Portfolio Grader’s complete analysis of PIP stock.
Biota Pharmaceuticals, Inc. (BOTA) gets a higher grade this week, advancing from a C last week to a B. Biota Pharmaceuticals is an anti-infective drug development company with expertise in respiratory diseases, particularly influenza. For more information, get Portfolio Grader’s complete analysis of BOTA stock.
This week, Northwest Biotherapeutics, Inc.’s (NWBO) ratings are up from a C last week to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
Emergent BioSolutions Inc. (EBS) boosts its rating from a C to a B this week. Emergent BioSolutions develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. For more information, get Portfolio Grader’s complete analysis of EBS stock.
The rating of Cepheid (CPHD) moves up this week, rising from a C to a B. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. For more information, get Portfolio Grader’s complete analysis of CPHD stock.
Incyte Corporation (INCY) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. Shares of INCY have increased 17.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of INCY stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
